Hadassah

Oral Insulin Pill, Based on Hadassah Medical Center Research, Cleared by FDA for Clinical Trial in US

Tuesday, May 21 2013

The oral insulin pill (ORMD-0801), based on over 30 years of research by Hadassah Medical Center scientists, and developed by the Israeli company, Oramed Pharmaceuticals Inc., has been cleared by the United States Food and Drug Administration (FDA) for Phase 2 clinical trials in the US.

The orally ingestible capsule is indicated for those with early stage type two diabetes, when it can slow the rate of disease progression by providing additional insulin to the body and allowing the pancreas a respite. The pill delivery system has the advantage of mimicking insulin's natural location and gradients in the body by first passing through the liver before entering the bloodstream. "We are very pleased to have the FDA clearance to proceed," stated Nadav Kidron, Chief Executive Officer of Oramed. "The upcoming trial is a major milestone for Oramed and we look forward to continuing to progress ORMD-0801's clinical development in the US."

Read more about the insulin pill from Hadassah International>>

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Jan 13 2017

Saving Children in the Nick of Time at Hadassah

When a four-year-old, blue and critically ill, was rushed into the pediatric emergency room at Hadassah Hospital Mount Scopus, Dr. David Rekhtman, head of the ER, and his team deciphered that the child had somehow consumed methadone.

READ MORE ›
alt_text

Friday, Jan 13 2017

Peace in Sight: An Israeli, Palestinian, and Hadassah Australia Collaboration

St. John of Jerusalem Eye Hospital, in collaboration with Hadassah Medical Center, has received a €500,000 grant from the European Union to establish a genetic research unit to serve the Palestinian communities.

READ MORE ›
alt_text

Friday, Jan 13 2017

A Second Chance at Life, Thanks to Hadassah’s Heart Institute

A resident of a rural settlement called Dishon, established by Libyan Jewish immigrants in 1953, Eyal Amar, age 47, was rather young to suffer a devastating heart attack. Nevertheless, he did, but thanks to the courage and skill of the specialists at the Hadassah Medical Organization’s Heart Institute and their complex protocol to redesign his heavily damaged heart, Eyal is able to walk and breathe again.

READ MORE ›
alt_text

Tuesday, Jan 10 2017

From Locked Jaw to Osteoarthritis: Hadassah Discovery Leads to New Treatment

What began as a solution to locked jaw--temporomandibular joint (TMJ) disorder--has led to the creation of a novel non-opioid pharmaceutical candidate for the treatment of osteoarthritis pain, thanks to a Hadassah Medical Organization discovery and collaboration with colleagues at the Hebrew University and the Technion.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More